Cronos Group Inc vs CarMax, Inc — how do they compare? Cronos Group Inc trades at $2.75 (market cap $1.02B), while CarMax, Inc trades at $59.26 (market cap $7.91B). The key difference: CarMax, Inc is far larger — about 7.8× Cronos Group Inc's market cap, and CarMax, Inc is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals.
| CRON | KMX | |
|---|---|---|
Market Cap | $1.02B | $7.91B |
Sector | Health | Consumer Cyclical |
52-Week High | $3.27 | $63.53 |
52-Week Low | $1.95 | $30.88 |
Enterprise Value | $203.29M | $26.42B |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
CarMax (KMX) trades at $54.87, up 2.58% today, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported Q1 2026 earnings that beat expectations, with EPS of $0.34 versus $0.23 expected, driven by cost controls and strategic execution. Revenue for 2025 was $26.35 billion, with net income of $500.56 million, though margins remain thin. Recent news highlights a four-pillar turnaround strategy under new CEO Keith Barr, with insider buying and positive analyst updates supporting sentiment.
The outlook for KMX hinges on successful execution of its growth strategy amid competitive pressures and margin challenges. While technical indicators suggest near-term strength, fundamental risks include high debt levels and fluctuating profitability. Analyst consensus is cautious with a hold-heavy rating, but the stock offers potential for recovery if operational improvements sustain. Investors should weigh the bullish technical setup against fundamental headwinds and ongoing investigations.
Trailing returns across standard periods
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →